Skip to content
OpenCapital
Get started

OrthoPediatrics KIDS Indefinite-Lived Intangible Assets

Indefinite-Lived Intangible Assets at other companies

Boston Scientific logo
Boston ScientificBSX
——

Other financials

Income statement

See full
Revenue$59.4M+13.3%
Gross profit$43.4M+13.4%
Operating income-$8.3M+24.1%
Net income-$10.7M-0.3%
EPS (diluted)-$0.45+2.2%

Balance sheet

See full
Cash & equivalents$14.2M-59.8%
Total debt$5.4M+271%
Total equity$338.7M-2.4%
Total assets$502.2M+6.8%

Cash flow

See full
Operating cash flow-$3.3M+20.9%
CapEx$1.8M-58.4%
Free cash flow-$5.0M+39.8%

Valuation

See full
Market cap$503.94M+0.3%
Enterprise value$495.11M+5.7%
P/S2.1×-0.3×

Profitability

See full
Gross margin73.1%+0.3pp
Operating margin-15%-1.6pp
Net margin-16.3%-2.1pp
FCF margin-12.9%-4.3pp

Returns & leverage

See full
Return on equity-11.6%+0.2pp
Debt / equity0×0.0×
Current ratio5.2×-1.0×

Where this comes from

Reported directly by OrthoPediatrics in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: OrthoPediatrics’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about OrthoPediatrics's indefinite-lived intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OrthoPediatrics's indefinite-lived intangible assets?
OrthoPediatrics (KIDS) reported indefinite-lived intangible assets of $12.91M in Q1 2026.
How has OrthoPediatrics's indefinite-lived intangible assets changed year-over-year?
OrthoPediatrics's indefinite-lived intangible assets decreased by 22.8% year-over-year, from $16.74M to $12.91M.
What is the long-term trend for OrthoPediatrics's indefinite-lived intangible assets?
Over 5 years (2020 to 2025), OrthoPediatrics's indefinite-lived intangible assets has grown at a -1.6% compound annual growth rate (CAGR), from $13.96M to $12.91M.
What does indefinite-lived intangible assets mean?
This represents intangible assets, such as iconic brand names or trademarks, that are expected to generate cash flows for an unlimited period. Unlike finite-lived assets, these are not amortized but are tested annually for impairment. They represent the core long-term value of the company's brand portfolio.